GFAP and Alzheimer disease: Plasma GFAP discriminated CU+ individuals from CU– individuals with an AUC of 0.75 to 0.79 in TRIAD, similar to the AUC of 0.795 previously described.16 Furthermore, in ALFA+, we studied the earliest phase of preclinical AD.